Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Targets for Therapy of Bladder Cancer
Christof Seidl
SEMINARS IN NUCLEAR MEDICINE (2020)
Context-dependent roles of complement in cancer
Lubka T. Roumenina et al.
NATURE REVIEWS CANCER (2019)
Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer
Manh-Hung Do et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers
Young-Suk Cho et al.
ONCOTARGET (2016)
The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack
Rebecca Kesselring et al.
EUROPEAN JOURNAL OF CANCER (2014)
Complement in monoclonal antibody therapy of cancer
Laura M. Rogers et al.
IMMUNOLOGIC RESEARCH (2014)
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer et al.
MABS (2014)
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma
Cindy Neuzillet et al.
CANCER AND METASTASIS REVIEWS (2013)
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi et al.
MOLECULAR ONCOLOGY (2013)
Boosting antibody therapy with complement
Peter Boross et al.
BLOOD (2012)
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Matthew J. Barth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers Infection
Hung V. Trinh et al.
JOURNAL OF VIROLOGY (2012)
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement
Nisar A. Baig et al.
LEUKEMIA & LYMPHOMA (2012)
Metastatic bladder cancer: anything new?
Fabio Calabro et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2012)
Best practice in the treatment of nonmuscle invasive bladder cancer
Anastasios Anastasiadis et al.
THERAPEUTIC ADVANCES IN UROLOGY (2012)
CD46 Expression is an Unfavorable Prognostic Factor in Breast Cancer Cases
Adam Maciejczyk et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
N. Geis et al.
CURRENT CANCER DRUG TARGETS (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Targeting the RAF-MEK-ERK pathway in cancer therapy
Clara Montagut et al.
CANCER LETTERS (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity
Bohua Li et al.
CANCER RESEARCH (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer
Wassim Kassouf et al.
JOURNAL OF UROLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients
NFS Watson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells
Hooi Tin Ong et al.
EXPERIMENTAL HEMATOLOGY (2006)
Complement function in mAb-mediated cancer immunotherapy
KA Gelderman et al.
TRENDS IN IMMUNOLOGY (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
CD46: expanding beyond complement regulation
RC Riley-Vargas et al.
TRENDS IN IMMUNOLOGY (2004)
GAP control: regulating the regulators of small GTPases
A Bernards et al.
TRENDS IN CELL BIOLOGY (2004)
MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors
JS Sebolt-Leopold
CURRENT PHARMACEUTICAL DESIGN (2004)
Tumor-specific inhibition of membrane-bound complement regulatory protein crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model
KA Gelderman et al.
CANCER RESEARCH (2004)
Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer?
Sriplakich et al.
BJU INTERNATIONAL (2003)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson et al.
MOLECULAR IMMUNOLOGY (2003)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Cytokines affect resistance of human renal tumour cells to complement-mediated injury
VT Blok et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2003)
Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity
TA Caragine et al.
BLOOD (2002)
Expression of complement regulating factors in gastric cancer cells
T Inoue et al.
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY (2002)
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies
KA Gelderman et al.
LABORATORY INVESTIGATION (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
